LYEL earnings analysis
What we found in LYEL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lyell Immunopharma reported a significant decline in revenue for Q1 2026, generating only $2 million compared to $7 million in Q1 2025. The gross margin remained at 100%, but the operating expenses decreased substantially from $57.4 million in Q1 2025 to $44.3 million in Q1 2026. Despite these reductions, the net loss improved notably to $24.15 million from a loss of $52.19 million a year prior. This underscores a continued focus on reducing cash burn while progressing towards pivotal trials for its leading therapies, ronde-cel and LYL273.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduction in Operating Expenses
- Operating expenses decreased from $57.4 million in Q1 2025 to $44.3 million in Q1 2026.
- Significant Improvement in Net Loss
- Net loss improved to $24.15 million from $52.19 million in the prior year.
- Increase in Other Income
- Other income increased to $20.11 million, driven by a gain from the change in fair value of the SPA put/call asset.
- Liquidity Position Stabilized
- Cash, cash equivalents, and marketable securities were reported at $261 million as of March 31, 2026.
- No New Debt Incurred
- The company reported no long-term debt outstanding as of March 31, 2026.
- Ongoing Clinical Activity
- Two pivotal trials for ronde-cel are still active, with expected data releases in 2026 and 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory Approval Uncertainty
- The FDA may require additional trials for product candidates, delaying commercialization.
- Persistent Cash Burn Risks
- Despite reducing operating expenses, cumulative cash burn remains a concern with $261 million available as of March 31, 2026.
- Intellectual Property Challenges
- Potential litigation over patent rights could undermine competitive advantage and lead to costly settlements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-24.15
- Gross margin
- 100%
What they said about what is next.
Management continues to emphasize cost containment and strategic prioritization of product development. Guidance for specific financial metrics is deferred to future communications.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 12, 2026
- Lyell Immunopharma Inc. reported a significant net loss of $274.4 million for the fiscal year ending December 31, 2025, compared to a loss of $343.0 million in 2024. Despite a decline in research and development…
- 10-Q · November 12, 2025
- Lyell Immunopharma reported third quarter results revealing a significant decrease in revenue to $15 million from $34 million year-over-year, alongside an improvement in diluted EPS, which narrowed the loss to -$2.13…
- 10-Q · August 12, 2025
- Lyell Immunopharma reported a revenue of $8.0 million in Q2 2025, reflecting a decline of $5.0 million from $13.0 million in Q2 2024. The company reported a diluted EPS of -2.89, slightly better than the estimated…
- 10-Q · May 13, 2025
- Lyell Immunopharma's Q1 2025 results show a significant decline in revenue and continuing losses, although gross margins remain constant at 100%. EPS reported at -0.18 indicates ongoing challenges. Management's focus on…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LYEL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever